Hormone research in paediatrics · 2024
Clinical Predictors of Good/Poor Response to Growth Hormone Treatment in Children with Idiopathic Short Stature.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dauber Andrew, Phillip Moshe, Ferran Jean-Marc, Kelepouris Nicky, Nedjatian Navid, Olsen Anne Helene, de Lima Jorge Alexander Augusto
Аннотация
INTRODUCTION: Children with idiopathic short stature (ISS) are known to have varying responses to growth hormone (GH) treatment (GHT).
METHODS: We conducted a post hoc analysis to identify clinical characteristics predictive of good and poor response during year 1 of GHT. Data from the NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905) were used. Patients were grouped according to their response to GHT; good, middle, and poor responders had a change in HSDS of >1.0, 0.4-1.0, and <0.4, respectively. Patients were also grouped according to their responsiveness to GH dose. Logistic regression modelling was performed to identify clinical characteristics predictive of response to GHT.
RESULTS: The response analysis set included 207 patients. Patients were 3-11 years old (males) or 3-10 years old (females) at the start of treatment and were prepubertal throughout year 1 of treatment. Age at the start of treatment (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.5; 0.9, p = 0.0169) and distance from target HSDS (OR: 2.05, 95% CI: 1.1; 3.9, p = 0.0259) were found to be significant independent predictors of being in the good- versus poor-response groups. When patients were grouped according to their responsiveness to GH dose, a positive correlation between GH dose and change in HSDS was observed.
CONCLUSION: We identified younger age and further distance from target HSDS as clinical predictors of response to GHT in a heterogenous population of children with ISS. Future studies, designed to identify the genetic determinants of response to GHT, could further facilitate individualisation of GHT.
METHODS: We conducted a post hoc analysis to identify clinical characteristics predictive of good and poor response during year 1 of GHT. Data from the NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905) were used. Patients were grouped according to their response to GHT; good, middle, and poor responders had a change in HSDS of >1.0, 0.4-1.0, and <0.4, respectively. Patients were also grouped according to their responsiveness to GH dose. Logistic regression modelling was performed to identify clinical characteristics predictive of response to GHT.
RESULTS: The response analysis set included 207 patients. Patients were 3-11 years old (males) or 3-10 years old (females) at the start of treatment and were prepubertal throughout year 1 of treatment. Age at the start of treatment (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.5; 0.9, p = 0.0169) and distance from target HSDS (OR: 2.05, 95% CI: 1.1; 3.9, p = 0.0259) were found to be significant independent predictors of being in the good- versus poor-response groups. When patients were grouped according to their responsiveness to GH dose, a positive correlation between GH dose and change in HSDS was observed.
CONCLUSION: We identified younger age and further distance from target HSDS as clinical predictors of response to GHT in a heterogenous population of children with ISS. Future studies, designed to identify the genetic determinants of response to GHT, could further facilitate individualisation of GHT.